AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

In a precedential opinion issued on March 6, the Federal Circuit affirmed the US District Court for the Eastern District of ...

Background: ImmunoGen’s Patent Application & Dispute. In 2014, ImmunoGen, Inc. (Immunogen) filed U.S. Patent Application No.

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

The US Court of Appeals for the Federal Circuit affirmed a district court decision rejecting claims of a patent application directed to a ...

The research team, led by Dr. Mihai Azoitei, associate professor at the Duke Human Vaccine Institute and the Department of Cell Biology, has created an immunogen -- a substance that provokes an ...

Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product ...

However, over the past decade, companies including Seattle Genetics and ImmunoGen have extensively researched the ideal characteristics of an ADC. “It took a while to figure out that you need to ...

In a precedential opinion issued on March 6, the Federal Circuit affirmed the US District Court for the Eastern District of Virginia that the claims in ImmunoGen’s US patent application 14/ ...

In addition to the 3D Epitope Mapping, Proteintech improved the display of its immunogen information. The immunogen data is now displayed as a bar graph at the top of the search return pages ...